Neuren Pharmaceuticals Appoints Zita Peach as Board Chair to Succeed Patrick Davies

Manish Choudhary

12 November 2026 10:15 AM AEDT

Neuren Pharmaceuticals Appoints Zita Peach as Board Chair to Succeed Patrick Davies

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Neuren Pharmaceuticals (ASX:NEU) has appointed Ms Zita Peach as Chair of the Board following a succession process, with Zita succeeding Patrick Davies, who has served as Chair since May 2020 and joined the Board in July 2018, the company disclosed on 12 November 2026.

Key Points

Zita Peach appointed Chair of Neuren Pharmaceuticals' Board of Directors, succeeding Patrick Davies.
Patrick Davies joined the Board in July 2018 and has served as Chair since May 2020.
Zita Peach brings more than 35 years of healthcare executive leadership across pharmaceuticals, biotechnology and medical devices.
Peach previously chaired ASX-listed Pacific Smiles Group from 2020 to 2024 and currently chairs the Olivia Newton-John Cancer Research Institute.
Peach holds a Bachelor of Science from the University of Melbourne and is a Fellow of the Australian Institute of Company Directors.

Zita Peach's Executive and Board Background

Zita Peach served as Executive Vice President, South Asia Pacific and Managing Director, Australia and New Zealand at Fresenius Kabi. Prior to that role, she spent a decade as Vice President, Business Development at CSL, leading licensing deals, partnerships, acquisitions, and early commercialisation of influenza vaccine internationally. Additional previous roles include Commercial Director at Merck Sharp & Dohme and helping build AMRAD Pharmaceuticals from its launch. She currently serves as a Non-Executive Director of Monash IVF Group, Icon Group, Nucleus Network and VetPartners, and has previously served as a Director of Starpharma, Visioneering Technologies and the Hudson Institute of Medical Research.

Patrick Davies' Tenure as Outgoing Chair

Patrick Davies joined the Neuren Pharmaceuticals Board in July 2018 and has served as Chair since May 2020. In a statement included in the filing, CEO and Managing Director Jon Pilcher described Davies as having provided exemplary leadership over his tenure. Davies commented in the filing that he is delighted with all that Neuren has achieved and cited Peach's deep experience in mergers and acquisitions, licensing, global commercialisation and board governance as assets for the company's growth strategy.

Neuren's Drug Development Programs

Neuren Pharmaceuticals is developing drug therapies targeting serious neurological disorders caused by genetic abnormalities or brain injury. DAYBUE (trofinetide) oral solution is approved for the treatment of Rett syndrome by the US Food and Drug Administration, the European Medicines Agency, Health Canada and the Ministry of Health in Israel. The company has granted an exclusive worldwide licence to Acadia Pharmaceuticals Inc. for the development and commercialisation of trofinetide. Neuren's investigative candidate NNZ-2591 (ercanetide) is in clinical development for multiple neurodevelopmental disorders, including Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome, with a Phase 3 trial currently underway for Phelan-McDermid syndrome.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.